A recombinant, fully humanized monoclonal antibody to interleukin-17 has been approved for the treatment of moderate-to-severe plaque psoriasis. Secukinumab is marketed by Novartis as Cosentyx.
Pharmacology Update
Secukinumab Injection (Cosentyx™)
March 30, 2015